Sun Pharma board to consider ₹15,000 crore NCD issue on Oct. 12
In short
Sun Pharma’s board will meet on October 12, 2026, to consider issuing non-convertible debentures worth up to ₹15,000 crore. The summaries say the money would help fund a bridge loan for buying Organon & Co.
This matters because the company is considering a large debt raise. The board has not approved it yet, and the final terms are still unknown.
What the reporting says
Sun Pharmaceutical Industries’ board will consider on October 12, 2026, a non-convertible debenture issue of up to ₹15,000 crore through private placement. Publisher summaries say the proceeds are intended to fund a bridge loan for the acquisition of Organon & Co. The decision is not yet approved, and the final structure and timing remain subject to the board’s vote.
Why it matters
Sun Pharmaceutical Industries is preparing for a board decision on October 12, 2026, about issuing up to ₹15,000 crore of non-convertible debentures by private placement. The reported purpose is to support a bridge loan tied to the acquisition of Organon & Co. The immediate market focus is on potential leverage and funding plans, but the board outcome is not yet known.